Periprocedural anticoagulation in ablation: choosing the safer pathway

Catheter ablation for atrial fibrillation has become a routine part of electrophysiology practice, yet the anticoagulation plan around the procedure remains a major determinant of safety. The central decision is whether oral anticoagulant therapy should continue without interruption or be withheld briefly before the intervention. That choice affects thromboembolism, access-site bleeding, cardiac tamponade management and the timing of discharge.

For most patients undergoing left atrial ablation, current practice has moved away from prolonged interruption and routine heparin bridging. An uninterrupted or minimally interrupted direct oral anticoagulant strategy can provide stable protection against thrombus formation while avoiding the peaks and troughs associated with stopping treatment and substituting low-molecular-weight heparin.

The best approach still depends on the drug, renal function, bleeding risk, procedural technique and local protocol. Australian electrophysiology units must also account for the availability of medicines through the Pharmaceutical Benefits Scheme, differences between public and private hospitals, and the needs of patients travelling from regional areas to centres in Sydney, Melbourne, Brisbane, Perth or Adelaide.

Why anticoagulation matters during left atrial ablation

Atrial fibrillation promotes blood stasis, particularly in the left atrial appendage. Catheter manipulation, transseptal puncture, tissue injury and periods of atrial stunning can add further prothrombotic risk. Even when the presenting rhythm has been restored to sinus rhythm, thromboembolic risk does not disappear immediately after ablation.

During a left atrial procedure, intravenous unfractionated heparin is generally administered after or around transseptal access, according to the operator’s technique. Activated clotting time is monitored repeatedly, with many laboratories targeting a range around 300–350 seconds, although the precise target and testing method vary. The objective is to prevent thrombus on sheaths and catheters while maintaining a manageable bleeding profile.

Anticoagulation planning must be separated from the patient’s longer-term stroke prevention plan. The CHA₂DS₂-VASc score, age, prior stroke, heart failure, hypertension, diabetes and vascular disease remain relevant after ablation. Successful rhythm control does not automatically justify stopping oral anticoagulation, particularly in patients with moderate or high baseline stroke risk.

The case for an uninterrupted approach

With warfarin, uninterrupted treatment has a long history in atrial fibrillation ablation. Maintaining a therapeutic international normalised ratio avoids the unstable anticoagulant effect that can follow cessation and bridging. Several studies have associated uninterrupted warfarin with fewer thromboembolic events and less major bleeding than a heparin-bridging strategy.

Direct oral anticoagulants have also become central to periprocedural management. Trials involving dabigatran, rivaroxaban, apixaban and edoxaban have supported uninterrupted or minimally interrupted use in experienced centres. Compared with warfarin, DOACs offer predictable pharmacokinetics and avoid routine INR testing, although timing is more sensitive to renal function, dose selection and adherence.

An uninterrupted schedule usually means taking the prescribed DOAC dose as normal, including a dose on the evening before or the morning of ablation depending on the drug and procedure time. A minimally interrupted schedule may omit a single dose, commonly the morning dose on the day of the procedure. These terms should be defined precisely in the local protocol because “uninterrupted” does not mean that every patient takes a dose immediately before anaesthesia.

When interruption may be appropriate

Short interruption can be reasonable when bleeding risk is unusually high, renal clearance is substantially impaired, drug accumulation is suspected or the timing of the last dose is uncertain. A patient who has missed several doses may require a different assessment from someone who has taken every dose reliably. Dabigatran deserves particular attention in advanced kidney disease because its elimination is more dependent on renal function than that of several factor Xa inhibitors.

Bleeding history, thrombocytopenia, liver disease, uncontrolled hypertension and concomitant antiplatelet treatment should be reviewed before admission. Recent gastrointestinal bleeding, complex vascular access or anticipated extensive ablation may influence the balance. Even then, prolonged interruption can expose the patient to avoidable embolic risk, and routine bridging with enoxaparin is generally not a default solution for DOAC-treated patients.

A transoesophageal echocardiogram or alternative imaging may be considered when anticoagulation has been inadequate, adherence is uncertain, cardioversion is recent or left atrial appendage thrombus is a concern. Imaging does not replace careful medication reconciliation. The procedural team should document the last dose, kidney function, weight, concurrent medicines and the intended time of resumption.

Practical management on the day

A clear medication pathway begins several days before admission. The electrophysiologist, anaesthetist, anticoagulation service and nursing team need a shared plan that specifies whether the oral anticoagulant is continued, which dose is withheld, and when the next dose will be taken. This is especially important where patients move between general practice, private cardiology rooms and a public hospital.

After vascular access is obtained, meticulous haemostasis is essential. Ultrasound-guided femoral puncture, careful sheath removal and observation for expanding haematoma can reduce avoidable complications. Protamine may be considered after the procedure when heparin reversal is needed, but its use must be balanced against the possibility of catheter-related thrombosis and the operator’s assessment of residual anticoagulant effect.

For a DOAC, resumption is commonly planned several hours after haemostasis is secure, often on the evening of the procedure or the following morning. Warfarin is usually continued or restarted promptly because its therapeutic effect is delayed. The patient should receive written instructions, including what to do after vomiting, missed doses, black stools, severe groin pain, neurological symptoms or sudden shortness of breath.

Australian hospitals may use different electronic medication charts and observation pathways, but the principle is consistent: the last pre-procedure dose and first post-procedure dose must be visible to every clinician involved. PBS-funded access to DOACs supports broad use, while restrictions, brand substitution and pharmacy supply can still create practical problems that need resolution before the admission date.

Special populations and procedural variation

Patients with mechanical heart valves require warfarin and should not be switched to a DOAC. Those with severe kidney disease, extremes of body weight, active cancer, pregnancy or significant liver dysfunction need individualised specialist advice. Frailty and falls risk should be considered, but falls alone rarely justify stopping anticoagulation when the stroke risk is substantial.

The same principles do not apply identically to every electrophysiology procedure. Right-sided flutter ablation generally carries less embolic risk than left atrial ablation, while complex ventricular tachycardia ablation can involve prolonged procedures, epicardial access and distinct bleeding considerations. Device implantation, lead extraction and cardiac resynchronisation therapy also require procedure-specific plans rather than automatic transfer of an AF ablation protocol. The evidence around CRT survival benefits illustrates why procedural context and long-term clinical goals should remain linked.

Patients with inherited arrhythmia syndromes may present for procedures or investigations in which anticoagulation is not the primary issue, but their overall risk profile still matters. A broader review of phenotype, family history and rhythm diagnosis can be valuable when planning care for people with unusual electrocardiographic findings, including the spectrum of J-wave syndromes.

Building a reliable local protocol

A high-quality protocol should begin with uninterrupted anticoagulation as the default for eligible patients, then identify explicit exceptions. It should state dose timing for each DOAC, management according to estimated glomerular filtration rate, acceptable INR ranges for warfarin, intraprocedural ACT targets and criteria for post-procedure resumption.

Audit is useful because complications may arise from process failures rather than the strategy itself. Centres can track stroke or transient ischaemic attack, major bleeding, groin complications, tamponade, unplanned admission and medication errors. Comparing results across Australian metropolitan and regional services may also reveal whether transfer delays, pharmacy access or inconsistent discharge communication influence outcomes.

Patient education should be practical rather than generic. Explain why anticoagulation continues after an apparently successful ablation, identify the exact next dose, and provide a contact pathway that works after discharge. For people travelling from Western Australia or remote Queensland to a tertiary centre, arrangements for local accommodation, follow-up blood tests when relevant and rapid assessment of bleeding are part of safe procedural care.

The final decision should be recorded in the operative plan and discharge summary, with responsibility assigned for reviewing renal function and future dose changes. A consistent multidisciplinary approach allows uninterrupted or minimally interrupted therapy to deliver its intended benefit: reducing embolic risk without creating preventable bleeding or medication confusion.

Electrophysiology teams can strengthen safety by reviewing their anticoagulation pathway against current evidence, local outcomes and the needs of their patient population. Clinicians and trainees can use peer-reviewed arrhythmia research to refine dose timing, monitoring and post-ablation follow-up, while patients should receive a personalised written plan before leaving hospital.